logo-loader
viewSeelos Therapeutics

Seelos Therapeutics to host key opinion leader call to discuss unmet medical needs in suicide and depression

The discussion will also focus on the group's SLS-002 intranasal racemic ketamine drug aimed at Acute Suicidal Ideation and Behavior (ASIB) in patients with major depressive disorder

Seelos Therapeutics -
The New York clinical-stage biopharmaceutical company is focused on central nervous system, neurological and psychiatric disorders

Seelos Therapeutics Inc (NASDAQ:SEEL) is set to host a key opinion leader call to discuss the unmet medical needs in suicide and depression, featuring an eminent academic and author.

The New York clinical-stage biopharmaceutical company is focused on central nervous system, neurological and psychiatric disorders. The compnay's SLS-002 intranasal ketamine depression drug is aimed at patients with Post-Traumatic Stress Disorder (PTSD) and major depressive disorder (MDD) at risk of committing suicide.

READ: Seelos Therapeutics' trehalose gets Rare Pediatric Disease Designation (RPDD) for treatment of Sanfilippo syndrome

The call will feature a discussion with Dr David V Sheehan, the University Health Professor Emeritus at the University of South Florida College of Medicine, who will discuss the unmet medical needs in treating suicidal patients with depression and other mental health conditions.

Dr Sheehan has written over 550 abstracts and 300 publications including a bestseller 'The Anxiety Disease', which has sold over 500,000 copies. 

He has been awarded over $20 million for 130 research grants and has  provided expert testimony to the Unites States Congress.. 

He was elected as a member of the American College of Psychiatrists and is a Distinguished Life Fellow of the American Psychiatric Association and is a Charter Member of the National Academy of Inventors.

Raj Mehra, the chairman and CEO of Seelos, will also discuss the group's lead candidate, intranasal racemic ketamine SLS-002 drug for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).

The call will be moderated by Mario Nacinovich, a member of the adjunct faculty at Boston University. He is also the founding editor of the Journal of Communication in Healthcare.

The call will take place on Tuesday, May 26 at 1pm  Eastern Time. Domestic callers can dial-in using 877-407-0789, while international callers can dial 201-689-8562. The conference ID is 13704179 and the webcast can be found HERE.

Quick facts: Seelos Therapeutics

Price: 1.1 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $49.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MagicMed Industries bring a fresh and unique approach to development of...

MagicMed Industries CEO Dr Joseph Tucker joined Steve Darling from Proactive Vancouver to talk about the company that intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products. Tucker telling Proactive about their...

3 weeks, 1 day ago

2 min read